DeCure for Hereditary breast ovarian cancer syndrome
DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for hereditary breast ovarian cancer syndrome — screening already-approved drugs against its 46-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHereditary breast ovarian cancer syndrome maps to a 46-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hereditary breast ovarian cancer syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
KRas proto-oncogene, GTPase (KRAS) — KRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gnpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7VVB · 1.7 Å · ligand PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER (GNP). Experimental structure, not a prediction.
What the evidence adds up to
Hereditary breast and ovarian cancer syndromes are inherited disorders that increase lifetime risk of breast and ovarian cancer, typically at younger ages than the general population. Cancer prevention in these syndromes includes prophylactic surgeries, personalised surveillance programmes, and chemopreventive strategies. Tamoxifen was the first agent considered for breast cancer prevention, followed by raloxifene and third-generation aromatase inhibitors. For ovarian cancer, the first and most widespread chemoprevention was combined hormonal contraceptive use. Although several strategies have shown promising results, only a few are currently applied in daily clinical practice. Side effects and psychological variables such as cancer perceived risk, worries, and related distress strongly influence women's decisions on chemoprevention.
A 2025 study examined gene expression profiles of DNA damage repair pathway genes — BRCA1, BRCA2, ATM, TP53, CHEK2, MRE11, RAD50, BARD1, PALB2, and NBN — in hereditary breast and ovarian cancer patients using quantitative real-time PCR. Most DNA damage repair genes were significantly upregulated in patients compared to controls, except MRE11, which was downregulated. Receiver operating characteristic curve analysis showed that MRE11 (p < 0.001), BRCA1 (p < 0.001), BRCA2 (p < 0.001), and PALB2 (p < 0.001) could serve as potential diagnostic biomarkers. Spearman correlation analysis indicated that RAD50 was significantly associated with BRCA1/2 mutation status (p = 0.05). Bivariate analysis revealed a strong positive correlation between BARD1 expression and expression of BRCA1, PALB2, and NBN. Kaplan-Meier survival analysis showed that reduced MRE11 expression was associated with better overall survival.
The identification of mutations in ovarian cancer predisposition genes plays a crucial role in cancer prevention, diagnosis, and treatment. In healthy carriers, detection of a specific mutation may justify more intensive surveillance programmes, chemopreventive measures, and prophylactic surgeries. In affected patients, mutation identification can guide treatment choices. Medical and genetic counselling of patients and their families helps develop diagnostic, preventive, and therapeutic measures aimed at monitoring healthy individuals and creating personalised treatment approaches.
What remains missing is large-scale prospective validation of MRE11 and other DNA repair genes as clinical biomarkers, alongside trials that stratify patients by these molecular markers. Chemoprevention studies still lack sufficient data on long-term adherence and the balance of side effects versus risk reduction in real-world populations. Funding for multi-centre trials that incorporate psychological and behavioural endpoints, rather than only biological ones, is needed before these findings can change practice.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Minerva Medica · 2019 · 22 citations · open access
Hereditary ovarian cancers: state of the art
AbstractThe identification of a mutation in ovarian cancer (OC) predisposition genes plays a crucial role in the management of cancer prevention, diagnosis, and treatment. In healthy carriers, the detection of a specific mutation might justify more intensive and personalised surveillance programmes, chemopreventive measures, and prophylactic surgeries. Moreover, the identification of a mutation in affected OC patients might provide fundamental knowledge of the tumour pathogenesis, thus guiding treatment choices. This is a comprehensive review of the molecular pathways involved in the pathogenesis of hereditary ovarian cancers, the clinical-pathological features of these tumours, and the potential implications for their prevention and clinical management.
The Scientific Notes of the Pavlov University · 2018 · 4 citations · open access
MEDICAL AND GENETIC COUNSELING OF HEREDITARY BREAST AND OVARIAN CANCER
AbstractHereditary breast and ovarian cancer is one of the most common genetic pathology. Medical and genetic counseling of patients with hereditary breast and ovarian cancer and their families plays the important role in cancer care, as it helps to develop the set of diagnostic, preventive and therapeutic measures aimed at monitoring healthy individuals and to create personalized approaches to the treatment of patients.
Chemoprevention strategies in hereditary breast and ovarian cancer syndromes
AbstractHereditary breast and/or ovarian cancer syndromes are inherited disorders in which there is an increased risk of developing breast and/or ovarian cancer in the lifetime, usually at a younger age compared to the general population. Cancer prevention in these syndromes includes prophylactic surgeries, personalized surveillance programs and chemopreventive strategies. Chemoprevention exploits the use of certain drugs or other substances to help lower the risk of developing cancer. In this context, tamoxifen was the first agent considered for breast cancer prevention, followed by raloxifene and the third-generation aromatase inhibitors. On the other hand, the first and most widespread type of chemoprevention for ovarian cancer was combined hormonal contraceptive use. Although several strategies have been studied and showed promising results, only a few of these are currently applied in daily clinical practice. Side effects along with several psychological variables such as cancer perceived risk, worries and related distress, strongly influence women's decision on chemoprevention. The present review explores and summarizes the available evidence on breast and ovarian cancer chemoprevention approaches.
Role of MRE11 in DNA damage repair pathway dynamics and its diagnostic and prognostic significance in hereditary breast and ovarian cancer
AbstractBACKGROUND: DNA damage repair pathway genes are key components for maintaining genomic stability and are mainly associated with hereditary breast and ovarian cancer. METHODS: The present study aimed to investigate the gene expression profile of DNA damage repair pathway genes, including BRCA1, BRCA2, ATM, TP53, CHEK2, MRE11, RAD50, BARD1, PALB2, and NBN, in hereditary breast and ovarian cancer patients using quantitative real-time PCR. RESULTS: The study showed significant upregulation of most DNA damage repair genes in HBOC patients compared to controls, except MRE11, which was downregulated. Receiver operating characteristic (ROC) curve analysis revealed that MRE11 (p < 0.001), BRCA1 (p < 0.001), BRCA2 (p < 0.001), and PALB2 (p < 0.001) can be used as potential diagnostic biomarkers for hereditary breast and ovarian cancer. Spearman correlation analysis showed that RAD50 was significantly associated with the BRCA1/2 mutation status (p = 0.05). Furthermore, bivariate analysis revealed a strong positive correlation between BARD1 gene expression and the expression of BRCA1, PALB2, and NBN genes. Kaplan-Meier survival analysis showed that reduces expression of the MRE11 gene was associated with better overall survival. CONCLUSIONS: The study findings may lead to a better understanding of the molecular mechanisms underlying hereditary breast and ovarian cancer, suggesting its role as a potential diagnostic and prognostic marker.
Journal of Nihon University Medical Association · 2021 · 0 citations · open access
Hereditary Breast Cancer and Ovarian Cancer (HBOC) Syndromeand Other Hereditary Tumors
AbstractThe special focus of this issue is “Women’s Medicine”. I have focused on hereditary breast cancer and ovariancancer (HBOC) syndrome and explained it in an easy-to-understand manner for readers who are not familiar withthis syndrome. Cancer genomic medicine and companion diagnostics have greatly changed the diagnosis andtreatment of HBOC syndrome as well as the cancer treatment system. In particular, the fact that preventive operations are covered by insurance is ground-breaking in Japan. Other hereditary tumors are summarized and outlinedin a table. The present manuscript provides valuable cancer information data not only for females but also formales with hereditary tumors.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
